HomeCompareOCEAW vs ORCC

OCEAW vs ORCC: Dividend Comparison 2026

OCEAW yields 6711.41% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEAW wins by $1097629163471472.38M in total portfolio value
10 years
OCEAW
OCEAW
● Live price
6711.41%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1097629163471472.38M
Annual income
$1,066,373,173,675,476,400,000.00
Full OCEAW calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — OCEAW vs ORCC

📍 OCEAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCEAWORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEAW + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEAW pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEAW
Annual income on $10K today (after 15% tax)
$570,469.80/yr
After 10yr DRIP, annual income (after tax)
$906,417,197,624,154,900,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, OCEAW beats the other by $906,417,197,624,154,900,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEAW + ORCC for your $10,000?

OCEAW: 50%ORCC: 50%
100% ORCC50/50100% OCEAW
Portfolio after 10yr
$548814581735736.19M
Annual income
$533,186,586,837,738,200,000.00/yr
Blended yield
97.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

OCEAW
No analyst data
Altman Z
-268.6
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEAW buys
0
ORCC buys
0
No recent congressional trades found for OCEAW or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCEAWORCC
Forward yield6711.41%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1097629163471472.38M$21.4K
Annual income after 10y$1,066,373,173,675,476,400,000.00$1.04
Total dividends collected$1095532211199846.75M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: OCEAW vs ORCC ($10,000, DRIP)

YearOCEAW PortfolioOCEAW Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$681,841$671,140.94$11,190$489.61+$670.7KOCEAW
2$43,496,987$42,767,417.65$12,229$256.01+$43.48MOCEAW
3$2,596,337,307$2,549,795,530.67$13,216$130.74+$2596.32MOCEAW
4$145,018,660,220$142,240,579,301.68$14,207$66.02+$145018.65MOCEAW
5$7,580,273,425,477$7,425,103,459,041.20$15,234$33.17+$7580273.41MOCEAW
6$370,837,750,892,272$362,726,858,327,011.50$16,317$16.62+$370837750.88MOCEAW
7$16,981,014,621,956,098$16,584,218,228,501,366.00$17,468$8.32+$16981014621.94MOCEAW
8$727,896,026,099,293,400$709,726,340,453,800,300.00$18,695$4.16+$727896026099.27MOCEAW
9$29,211,205,416,818,827,000$28,432,356,668,892,580,000.00$20,006$2.08+$29211205416818.81MOCEAW
10$1,097,629,163,471,472,400,000$1,066,373,173,675,476,400,000.00$21,407$1.04+$1097629163471472.38MOCEAW

OCEAW vs ORCC: Complete Analysis 2026

OCEAWStock

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Full OCEAW Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this OCEAW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEAW vs SCHDOCEAW vs JEPIOCEAW vs OOCEAW vs KOOCEAW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.